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Abstract  
The human voltage-gated sodium channel sub-type 1.7 (hNaV1.7) is emerging as an attractive target for the 
development of potent and sub-type selective novel analgesics with increased potency and fewer side effects 
than existing therapeutics. HwTx-IV, a spider derived peptide toxin, inhibits hNaV1.7 with high potency and 
is therefore of great interest as an analgesic lead. In the current study we examined whether engineering a 
HwTx-IV analogue with increased ability to bind to lipid membranes would improve its inhibitory potency 
at hNaV1.7. This hypothesis was explored by comparing HwTx-IV and two analogues [E1PyrE]HwTx-IV 
(mHwTx-IV) and [E1G,E4G,F6W,Y30W]HwTx-IV (gHwTx-IV) on their membrane-binding affinity and 
hNaV1.7 inhibitory potency using a range of biophysical techniques including computational analysis, NMR 
spectroscopy, surface plasmon resonance, and fluorescence spectroscopy. HwTx-IV and mHwTx-IV 
exhibited weak affinity for lipid membranes, whereas gHwTx-IV showed improved affinity for the model 
membranes studied. In addition, activity assays using SH-SY5Y neuroblastoma cells expressing hNaV1.7 
showed that gHwTx-IV has increased activity at hNaV1.7 compared to HwTx-IV. Based on these results we 
hypothesize that an increase in the affinity of HwTx-IV for lipid membranes is accompanied by improved 
inhibitory potency at hNaV1.7 and that increasing the affinity of gating modifier toxins to lipid bilayers is a 
strategy that may be useful for improving their potency at hNaV1.7.  
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 3 
Highlights 
 gHwTx-IV, an analogue of HwTx-IV, shows increased membrane binding. 
 Interactions between gHwTx-IV and the membrane appear to be electrostatic. 
 Increased membrane binding is accompanied by increased potency at hNaV1.7. 
 
 
Keywords: drug design; peptide-membrane interactions; venom peptide; huwentoxin; pain therapeutic; 
gating modifier toxin 
 
 
Abbreviations  
BSA, bovine serum albumin; CHOL, cholesterol; C1P, ceramide-1-phosphate; FLIPR
TETRA
, fluorescence 
imaging plate reader; GMT, gating modifier toxin; HBS, HEPES buffered saline; ICK, inhibitory cystine 
knot; LUV, large unilamellar vesicle; hNaV, human voltage-gated sodium channel; POPC, 1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphocholine; POPS, 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-L-serine; PSS, 
physiological salt solution; SAR, structure-activity relationship; SM, sphingomyelin; SPR, surface plasmon 
resonance; SUV, small unilamellar vesicle; TFA, trifluoroacetic acid; TIPS, triisopropylsaline. 
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1. Introduction 
There is a compelling need to improve currently available therapies for severe and chronic pain [1, 
2]. Voltage-gated ion channels located on sensory neurons are involved in the transmission of pain signals to 
the central nervous system for interpretation and response. Some sub-types of the human voltage-gated 
sodium channels (hNaVs), including the sub-type 1.7 (hNaV1.7), have been linked to pain [3, 4]. Loss of 
function mutations on SCN9A, the gene encoding hNaV1.7, result in unresponsiveness to pain, whereas gain 
of function mutations result in increased chronic and acute pain sensations [3, 4]. Because of this link to 
pain, efforts to identify potent and selective inhibitors of hNaV1.7 are underway [5-8]. 
Peptide toxins isolated from spider venoms have shown promising potency for inhibiting hNaV1.7 
and therefore have potential as therapeutic leads [9]. Most of these toxins modify the kinetics and gating 
behavior of voltage-gated ion channels and alter the relative stability of the closed, open or inactivated states 
of the channels. The peptide toxins are thus classified as gating modifier toxins (GMTs) [10].  
GMTs typically have a conserved amino acid arrangement resulting in a surface profile comprising a 
hydrophobic patch surrounded by a ring of charged residues (Figure 1B) [9, 11]. Structure activity 
relationship studies between the toxins and their target channels reveal that this surface motif appears to be 
involved in the binding of GMTs to target residues on the voltage-gated ion channels and that these peptides 
recognize overlapping target residues on the channels [12-14]. For example, the channel binding region of 
ProTx-II has been determined to bind to F813, D816 and E818 on hNaV1.7, whereas HwTx-IV has been 
shown to interact with E811, L814, D816, E818 on the same channel [15, 16]. This raises the possibility that 
the toxins, rather than recognizing specific channel residues, identify a local binding site on the voltage 
sensor domain that is structurally and chemically complementary to the surface motif of the GMTs [12, 17]. 
ProTx-II is an example of a GMT whose inhibitory activity has been suggested to be dependent on 
ability of the peptide to bind to lipid membranes [18]. This mechanistic suggestion is based on studies 
showing that ProTx-II analogues with reduced or no binding affinity to lipid membranes were shown to be 
inactive against hNaV1.7 whereas native ProTx-II, a potent inhibitor of hNaV1.7 (IC50 = 0.3 nM) showed 
affinity for lipid membranes [18]. Interestingly, HwTx-IV, despite showing a high potency at hNaV1.7 (IC50 
= 27 nM), binds poorly to tested model membranes [19]. In the current study we examined whether 
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engineering a HwTx-IV analogue with increased ability to bind to lipid membranes would improve its 
inhibitory potency at hNaV1.7 (Figure 1C). Biophysical studies were used to characterize peptide–membrane 
binding on model membranes and inhibitory potency at hNaV1.7 was studied using bioassays on SH-SY5Y 
neuroblastoma cells. The combined results showed that increasing the membrane binding affinity of HwTx-
IV also increased the inhibitory potency of the peptide toxin and these insights have the potential for 
translation to the design of analgesic inhibitors of hNaV1.7. 
 
2. Materials and methods 
 
2.1. Peptide synthesis and folding 
 
HwTx-IV, mHwTx-IV and gHwTx-IV (Figure 1C), were synthesized on a rink-amide resin at a scale 
of 0.25mmol to produce C-terminal amidated peptides employing standard automated 9-
fluorenylmethoxycarbonyl (FMOC) solid phase peptide synthesis (SPPS) using a Symphony peptide 
synthesizer (Protein Technologies Inc). The peptides were cleaved from the resin with simultaneous removal 
of side chain protecting groups by incubation with trifluoroacetic acid (TFA)/triisopropylsilane (TIPS)/water 
(48:1:1) (v/v/v) for 2.5 h. The resin was filtered and TFA was evaporated under vacuum prior to 
precipitation with ice-cold diethyl ether. The peptides were then extracted in 45% acetonitrile (ACN) (v/v) 
containing 0.05% TFA (v/v)) and lyophilized. The reduced peptides were purified by reversed phase high-
performance liquid chromatography (RP-HPLC) on a linear gradient of 5–55% solvent B (90% v/v ACN; 
0.05% v/v TFA) over 50 min at 50 mL/min. Fractions were collected and analyzed using ESI-MS and 
fractions of interest were pooled, lyophilized and stored at –20 °C. 
HwTx-IV and mHwTx-IV were oxidized overnight at room temperature at a concentration of 0.1 
mg/mL in 0.1 M Tris-HCl (pH 8), 0.1 M NaCl, 5 mM reduced glutathione and 0.5 mM oxidized glutathione 
[20]. Oxidation reactions were monitored using LC/MS and quenched with solvent A (0.05% v/v TFA) to 
1:2 (v/v). gHwTx-IV was dissolved in 50% v/v ACN prior to drop-wise addition to a buffer consisting of 0.1 
M Tris-HCl, 10% v/v filtered isopropanol (pH 8), 5 mM reduced glutathione and 1 mM oxidized glutathione 
bringing the final peptide concentration to 0.05 mg/mL. The reaction was quenched by lowering the pH to 
pH 2 using ACN/TFA/water (1:1:1) (v/v/v) [21].  
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Oxidized peptides were purified using a linear gradient of 10–70% solvent B over 60 min at 8 
mL/min and further separated at 3 mL/min on a gradient of 20–50% solvent B over 60 min. Fractions were 
collected and analyzed by ESI-MS. Fractions containing the molecular mass corresponding to the oxidized 
peptide were pooled, lyophilized and stored at –20 °C.  
Peptide samples were quantified by absorbance at 280 nm using Nanodrop. Extinction coefficients 
(280) of each peptide were calculated from the contribution of aromatic residues and disulfide bonds of the 
GMTs as follows: HwTx-IV 280 = 7365 M
-1cm-1, mHwTx-IV 280 = 7330 M
-1cm-1 and gHwTx-IV 280 = 
17430 M
-1cm-1. 
2.2. NMR spectroscopy 
 
HwTx-IV, mHwTx-IV and gHwTx-IV were dissolved in 90% (v/v) H2O and 10% (v/v) D2O to a 
concentration of ~1mg/mL at pH ~4. Experiments, including one-dimensional (1D) 
1
H spectra and two-
dimensional (2D) total correlated spectroscopy (TOCSY) (80 ms mixing time) and nuclear Overhauser 
effect spectroscopy (NOESY) (200 ms mixing time) were acquired on a Bruker Avance 600 MHz nuclear 
magnetic resonance (NMR) spectrometer equipped with a cryoprobe at 298 K to confirm correct folding of 
the peptides. Spectra were processed using TopSpin (Bruker), referenced to water at 4.76 ppm, and the 
peptide sequences were sequentially assigned using CCPNMR Analysis 2.4.1 [22, 23]. 
Additional NMR data were collected for the solution structure determination of gHwTx-IV, 
including 
1
H-
13
C HSQC and 
1
H-
15
N HSQC spectra in 90% (v/v) H2O and 10% (v/v) D2O in addition to 
TOCSY, NOESY and exclusive correlation spectra (E.COSY) spectra in 100% D2O. Amine proton 
temperature coefficients were derived from a series of TOCSY experiments run on a Bruker 500 MHz NMR 
spectrometer in 5 K increments (283–308 K). Manually assigned intra-residue and sequential NOEs for 
gHwTx-IV were used to generate a list of inter-proton distances using the AUTO function in CYANA 3.97 
[24]. Several rounds of AUTO calculations were used to refine peak assignments. Constraints for  and  
backbone dihedral angles were generated with TALOS-N using H, C, C, HN chemical shifts derived 
from NOESY,
 1
H-
13
C HSQC and 
1
H-
15
N HSQC spectra [25]. H-bond restraints derived from temperature 
coefficient experiments and D2O exchange experiments and 1 side chain dihedral angle restraints derived 
from E.COSY in combination with NOE intensities were included in structure calculations using the 
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ANNEAL function in CYANA. Protocols in the RECOORD database were used in CNS to calculate 50 
structures, which were further refined in a water shell [26, 27]. A final set of 20 structures was then chosen 
based on the lowest energy, fewest violations, and the best MolProbity scores and submitted to the Protein 
Data Bank (PDB ID: 5TLR) and the Biomagnetic Resonance Data Bank (BMRB: 30190) (Table 1) [28]. 
2.3. Molecular modelling of HwTx-IV and gHwTx-IV 
 
Solvent accessible surface area (SASA), residual dipole moments and electrostatic surface potentials 
of HwTx-IV and gHwTx-IV were calculated and analysed using the following molecular modelling tools. 
Polar and apolar SASA of the GMTs was calculated on GetArea using the default 1.4 Å water probe [29]. 
As HwTx-IV and gHwTx-IV are charged molecules, the dipole of these molecules is not formally defined 
and any calculated dipole is dependent on the translation or rotation of the peptides with respect to the 
origin. To facilitate a qualitative comparison between HwTx-IV and gHwTx-IV, the residual dipole 
moment, which is independent of position or rotation in space [30], was used. The residual dipole moment 
of HwTx-IV and gHwTx-IV was calculated using the g_dipoles tool on GROMACS version 5.1.12 in which 
the net charge is subtracted at the center of mass of the peptides [31]. Electrostatic surface potentials were 
calculated by solving the linearized Poisson-Boltzmann equation using the APBS software [32]. The PDB 
files of HwTx-IV (PDB ID: 2M4X) and gHwTx-IV (PDB ID: 5TLR) were processed using the PDB2PQR 
online server with the AMBER force field [33], and ProPka was used to assign protonation states of the side 
chains at a pH of 7.4 [27]. The electrostatic surface potential was visualized using the APBS plugin on 
PyMOL [34, 35]. 
2.4. Preparation of lipid vesicles 
 
 Synthetic 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1-palmitoyl-2-oleoyl-sn-
glycero-3-phospho-L-serine (POPS), ceramide-1-phosphate (C1P) and sphingomyelin (SM) were obtained 
from Avanti Polar Lipids. Synthetic cholesterol (CHOL) was obtained from Sigma Aldrich. Lipids were 
dissolved in spectroscopic grade chloroform and the required amounts combined to obtain mixtures of 
POPC, POPC/POPS (4:1 molar ratio) POPC/SM/CHOL (2.7:4:3.3 molar ratio), or POPC/C1P/CHOL 
(2.7:4:3.3 molar ratio). Lipid films were dried under a stream of N2 and left in vacuo overnight to remove 
any remaining solvent. The lipid films were re-suspended in HEPES buffered saline (HBS) (10 mM HEPES, 
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150 mM NaCl, pH 7.4), submitted to eight freeze-thaw cycles and extruded through 50 nm or 100 nm pore 
sized polycarbonate filters to obtain small unilamellar vesicles (SUVs) or large unilamellar vesicles (LUVs) 
respectively. SUVs were used for the surface plasmon resonance (SPR) studies as their small radii facilitate 
the formation of lipid bilayers when deposited onto the L1 SPR sensor chip. LUVs were used for 
fluorescence experiments as their large radii create a more planar surface to mimic the physiological lipid 
bilayers [36, 37]. 
2.5. Peptide–membrane kinetic and affinity studies using SPR 
 
 SPR was used to examine peptide–membrane binding kinetics and affinity. Experiments were 
conducted at 25 °C using a Biacore 3000 instrument and an L1 sensor chip. HBS was used to prepare the 
peptide and lipid samples and as running buffer. Lipid bilayers were deposited onto the surface of the L1 
sensor chip for 2600 s at a flow rate of 2 L/min as previously described [18]. Peptide samples 
(concentrations ranging from 0–64 M) were injected over the lipid surface for 180 s at a flow rate of 5 
μL/min for the association phase. The dissociation phase lasted 600 s per injection cycle. Data were 
corrected for buffer contribution and normalized by assuming that 1 response unit (RU) = 1 pg/mm
2 
of lipid
 
deposited, and subsequent peptide binding as previously described [38]. Peptide–lipid membrane binding 
was analysed using non-linear regression one-site specific binding curves on Prism 7. Binding kinetics were 
studied by fitting the data of peptides at 32 M to association then dissociation curves based on the 1:1 
Langmuir model [39]. 
2.6. Peptide–membrane binding followed by Trp fluorescence 
 
 The peptides used in this study are intrinsically fluorescent due to the presence of Trp residue(s) in 
their sequences. Trp fluorescence emission spectra were therefore used to examine whether the Trp 
residue(s) of the peptides insert into the lipid bilayers [40]. Peptides and L-Trp (12.5 M in HBS) were 
titrated with POPC/POPS (4:1) LUV suspensions to attain final lipid concentrations ranging from 0–4 mM. 
Fluorescence emission spectra were obtained upon excitation at 280 nm using a Perkin Elmer luminescence 
LS spectrometer with slits set to 3/3 nm. Peptide spectra were corrected for dilution due to titration with 
LUV suspensions and blanks were subtracted to examine changes in Trp fluorescence quantum yield. 
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Spectra were normalized to the maximum fluorescence emission intensity to delineate a potential blue shift 
in fluorescence emission. 
To examine whether the peptide Trp residues are solvent exposed when the peptides are in the 
presence or absence of LUVs, samples of GMTs or L-Trp (12.5 M in HBS) with or without 1 mM 
POPC/POPS (4:1) LUVs were titrated with acrylamide, an aqueous quencher, in concentrations ranging 
from 0–100 mM. Fluorescence emission intensity, upon excitation at 290 nm and emission at the 
wavelength at which the sample showed maximum emission (around 350 nm), was followed upon titration 
with acrylamide [40]. Data were corrected for dilution by titration with acrylamide and for dispersion from 
the lipid analysed using the Stern-Volmer equation [40]. 
2.7. Inhibition of hNaV1.7 induced by HwTx-IV and its analogues 
 
The inhibitory potency of HwTx-IV and two analogues on hNaV1.7 was assessed using a calcium 
assay on a Fluorimetric Imaging Plate Reader (FLIPR
TETRA
) assay as previously described [41]. SH-SY5Y 
cells expressing hNaV1.7 were maintained in RPMI medium supplemented with 15% (v/v) fetal bovine 
serum (FBS), 100 units/mL penicillin, 100 units/mL streptomycin and 2 mM L-glutamine, with subculturing 
every 72 h (70–80% confluence).  
SH-SY5Y cells were plated onto 96 well black-walled Corning™ imaging plates at a density of 
65,000 cells/well 72 h prior to FLIPR
 TETRA
 assays. Immediately prior to assays, media was removed and 
cells were washed in physiological salt solution (PSS: 140 mM NaCl, 11.5 mM glucose, 5.9 mM KCl, 1.4 
mM MgCl2, 1.2 mM NaH2PO4, 5 mM NaHCO3, 1.8 mM CaCl2 and 10 mM HEPES, pH 7.4). The SH-SY5Y 
cells were then incubated for 30 min at 37
 
°C with FLIPR calcium 4 dye, 30 nM of OD1 (a selective 
modulator of hNaV1.7 inactivation), and 0.1% (w/v) bovine serum albumin (BSA) diluted in PSS buffer as 
previously described [41]. Peptides were prepared to achieve final concentrations ranging from 3 M to 1.7 
 10-5 M in PSS with 0.1% (w/v) BSA. The NaV1.7 agonist, veratridine, was prepared to achieve a final 
concentration of 4 M in PSS with 0.1% (w/v) BSA. Test peptides were added to the cells and incubated for 
an additional 15 min using the FLIPR
TETRA
 instrument at 25
 
°C. Fluorescence emission intensity (excitation 
470–495 nm; emission 515–575 nm) was recorded every second for ten initial baseline reads, followed by 
the addition of veratridine. Fluorescence emission intensity (a measure of calcium influx into the cells 
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following veratridine activation of hNaV1.7) was then recorded every second for 300 s and the raw data were 
corrected for the contribution of buffer and transformed to maximal response over baseline using 
Screenworks 3.1.1.4 (Molecular Devices). Data were normalized to the maximal change in fluorescence 
emission for each peptide prior to analysis on Prism 7 using one-site specific binding with Hill slope and 
Bmax = 1.  
 
3. Results 
 
The purpose of this study was to determine whether increasing the membrane binding properties of 
HwTx-IV would increase its inhibitory at hNaV1.7. To achieve this goal, two analogues of HwTx-IV, 
[EPyrE]HwTx-IV (mHwTx-IV) and [E1G,E4G,F6W,Y33W]HwTx-IV (gHwTx-IV), were studied (Figure 
1C). mHwTx-IV is a naturally occurring derivative of HwTx-IV characterized by a post-translational 
modification conferring a pyroglutamic acid (PyrE) residue at position 1. The E1PyrE modification on 
mHwTx-IV has been determined previously to result in a longer duration of inhibition of hNaV1.7 [42]. 
gHwTx-IV is a derivative of another HwTx-IV analogue: [E1G,E4G,Y33W]HwTx-IV, shown previously to 
have increased potency at hNaV1.7 (IC50 = 0.4 nM) compared to HwTx-IV (IC50 = 27 nM)  [21].  
3.1. Peptide synthesis and NMR analyses on HwTx-IV, mHwTx-IV and gHwTx-IV 
 
All peptides in this study were successfully synthesized and oxidized with final yields of > 90% for 
HwTx-IV and mHwTx-IV and approximately 10% for gHwTx-IV. 1D 
1
H and 2D TOCSY and NOESY 
spectra were obtained for HwTx-IV, mHwTx-IV and gHwTx-IV. All peptides were confirmed to be folded 
as was evidenced by well dispersed peaks in the amide region (7–10 ppm) of the 1D 1H spectra. TOCSY and 
NOESY spectra were then used for the successful sequential assignment of individual amino acid spin 
systems [23]. H chemical shifts were used to compare mHwTx-IV and gHwTx-IV to native HwTx-IV. 
Overall, there were minimal chemical shift differences except at, or near positions on mHwTx-IV and 
gHwTx-IV where sequence modifications were present (Figure 2A). This observation indicated that the 
three synthetic peptides have similar overall structures and the same disulfide connectivity. 
The NMR solution structure of gHwTx-IV was calculated and refined using CYANA and CNS. The 
20 final structures were based on 395 distance restraints, including 130 intraresidue, 134 sequential, 36 
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medium range (|i – j| < 5), 90 long range (|i – j| >5 and 10 hydrogen bond distance restraints. In addition, 42 
dihedral angle restraints composing 18 , 19  and 5 1 angle restraints were included (Table 1). The final 
20 structures were selected based on low overall energies, two or fewer violations from experimental 
restraints, and satisfactory MolProbity scores (Figure 2B). The 20 conformers were superimposed and gave 
an overall global backbone RMSD of 0.99 ± 0.34 Å and a global heavy RMSD of 1.72 ± 0.38 Å. Not 
including the flexible N- and C-termini (residues 1 and 32-35), global backbone RMSD was 0.59 ± 0.13 Å 
and global heavy RMSD was 1.34 ± 0.17 Å (Table 1). The solution structure of gHwTx-IV was 
characterised by an ICK motif typical of spider derived GMTs [9]. The ICK structure featured loops and 
turns as well a pair of short antiparallel beta sheets between residues 23–24 and 31–32; features common to 
ICK peptides [43]. 
3.2. Peptide–lipid bilayer kinetic and affinity studies using SPR 
 
Peptide–lipid bilayer interactions of HwTx-IV and its analogues were studied using SPR and model 
membranes of varying charge and fluidity. Choice of model membranes in this study was based on features 
of the eukaryotic cell membrane, which exists as a heterogeneous fluid bilayer. Phospholipids containing a 
phosphatidylcholine headgroup are the most abundant lipids in eukaryotic cell membranes, thus vesicles 
composed of POPC, which forms zwitterionic fluid model membranes at 25 C, were used as an initial 
simple model membrane [44]. Negatively-charged vesicles composed of POPC/POPS (4:1) were used to 
examine the importance of electrostatic interactions between the peptide and the membrane and to mimic the 
effect of having negatively-charged molecules at the cell surface. Although the lipids that compose the outer 
leaflet of the cell membrane are primarily neutrally charged, there are anionic molecules present in the outer 
leaflet of physiological membranes [44] (e.g. extracellular regions of NaV channels and proteoglycans that 
possess a serine to which glycosaminoglycan chains are attached to [45]). The membrane environments in 
the vicinity of ion channels are proposed to have lipids arranged in domains (rafts) whose compositions 
typically have high proportions of CHOL and SM; furthermore, studies have shown that the venoms of some 
spiders have enzymes that drive the conversion of SM to the anionic ceramide-1-phosphate (C1P) [46, 47]. 
Therefore, the neutrally charged, POPC/SM/CHOL (2.7:4:3.3) and anionic POPC/C1P/CHOL (2.7:4:3.3 
molar ratio) model membranes were also studied [48, 49]. 
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The SPR data showed that gHwTx-IV has higher affinity and binding maxima in the four model 
membranes studied when compared to HwTx-IV and mHwTx-IV (Figure 3A, B). Furthermore, gHwTx-IV 
had preferential interactions (higher binding maxima and slower dissociation-rates) with the anionic 
POPC/POPS (4:1) and POPC/C1P/CHOL (2.7:4:3.3), in comparison to neutral POPC and POPC/SM/CHOL 
(2.7:4:3.3) model membranes (Table 2).  
3.3. In-depth location of peptide Trp residues within the lipid membrane 
 
 Fluorescence emission of Trp residues on peptides is sensitive to the surrounding environment; thus 
Trp fluorescence emission properties of peptides in the presence and absence of model membranes can be 
used to examine whether Trp residues are involved in the interaction between the peptide and the lipid 
membrane. The Trp fluorescence emission profile of gHwTx-IV and HwTx-IV was followed upon titration 
with LUV suspensions. Whereas the Trp fluorescence emission profile of HwTx-IV did not change upon 
titration with POPC/POPS (4:1) vesicles, there was a blue shift of 7 nm with no considerable change in the 
quantum yield in the fluorescence emission spectra of gHwTx-IV upon titration with lipid vesicles to a 
concentration of 4 mM (Figure 3C). These results show that in the presence of lipid, the Trp residues on 
gHwTx-IV become less exposed to the aqueous environment, and suggest that the residues are involved in 
the binding of the peptide to the lipid bilayer.  
Acrylamide is a water-soluble quencher of fluorescence emission from Trp residues on peptides and 
is unable to partition into lipid bilayers and thus can only efficiently quench fluorescence emission of Trp 
residues that are aqueous exposed. When Trp residues on peptides insert into lipid membranes they are 
protected from acrylamide quenching; therefore, the Trp fluorescence quenching efficiency by acrylamide in 
the presence of lipid vesicles was examined to give information on the position of the Trp residues when the 
peptides interact with lipid bilayers. The quenching efficiency of acrylamide was compared using the Stern 
Volmer constant (KSV) [37, 40]. Acrylamide efficiently quenched the fluorescence emission of the Trp 
residues of HwTx-IV and gHwTx-IV in buffer suggesting that the Trp residues of the peptides are solvent 
exposed and not buried in the core of the peptide structures. The acrylamide quenching of the Trp residue on 
HwTx-IV (KSV = 48.4 ± 1.2 M
-1
) was comparable to the negative control (L-Trp) (KSV = 49.1 ± 2.5 M
-1
) in 
the presence of 1 mM POPC/POPS (4:1) LUVs supporting the observation that HwTx-IV does not insert 
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into the membrane. Acrylamide was a less efficient quencher of the Trp fluorescence emission of gHwTx-
IV in the presence of POPC/POPS (4:1) LUVs (KSV = 37.5 ± 1.5 M
-1
) than in buffer (KSV = 44.1 ± 2.0 M
-1
) 
(Figure 3D). The small difference in KSV values suggests that the Trp residues in gHwTx-IV have a shallow 
position when bound to lipid membranes such that the residues are still accessible to acrylamide.  
3.4. Comparison of charge and surface properties of HwTx-IV and gHwTx-IV 
 
 To examine the features that confer gHwTx-IV with the ability to interact with lipid bilayers, we 
compared the net charge, residual dipole moment, solvent accessible surface area (SASA), electrostatic 
surface potentials and chemical surface profiles of gHwTx-IV and HwTx-IV. It can be expected that 
mHwTx-IV would show similar surface properties to HwTx-IV given the overall similarity in their 
structures based on secondary H shifts, and the only charge difference being the absence of a Glu residue 
at position 1 (Figure 2A). gHwTx-IV, on the other hand, has a higher net charge (+6 compared to +4 for 
HwTx-IV) as well as a higher residual dipole moment and more apolar SASA than HwTx-IV (Table 3). A 
surface profile comparison showed that gHwTx-IV had a larger hydrophobic surface area than HwTx-IV 
(Figure 5A). Furthermore, a comparison of the GMT electron density distributions showed that the surface 
of gHwTx-IV possessing the mutations was more positive than the same surface on HwTx-IV (Figure 5B). 
These results are attributable to the replacement of the anionic E1, E4, with the apolar G1, and G4 and the 
replacement of F6, Y33 more hydrophobic W6 and W33. 
3.5. Inhibitory activity of HwTx-IV, mHwTx-IV and gHwTx-IV at hNaV1.7 
 
To determine whether gHwTx-IV, the analogue that showed increased lipid bilayer interactions, 
would also show increased inhibitory activity at hNaV1.7, the FLIPR
 
calcium 4 assay was performed using 
SH-SY5Y neuroblastoma cells as previously described [41]. The three peptides slowed down the activation 
kinetics of hNaV1.7 (Figure 4A). HwTx-IV (IC50 = 32.4 ± 4.7 nM) and mHwTx-IV (IC50 = 30.8 ± 5.2 nM) 
had similar inhibitory activity; whereas gHwTx-IV showed an increase in inhibitory potency (IC50 = 7.6 ± 
1.5 nM) at hNaV1.7 (Figure 4B). 
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4. Discussion  
The structures of GMTs isolated from spiders are typically characterized by a conserved 
hydrophobic patch surrounded by a charged ring. This structural feature has been proposed to promote not 
only GMT–voltage-gated ion channel interactions, but also GMT–lipid membrane interactions [12, 13, 17, 
18, 48]. Several spider GMTs have been shown to interact with model membranes and the unique structures 
of these peptides have been proposed to facilitate a tri-molecular interaction involving the GMTs, the lipid 
membrane and target voltage-gated ion channels [14, 47, 50-52]. HwTx-IV is a potent inhibitor of hNaV1.7; 
however, this GMT has been reported to have a weak affinity for lipid membranes [16, 19]. In this study we 
confirm that HwTx-IV has weak membrane affinity and we compare the peptide to two analogues, mHwTx-
IV and gHwTx-IV. Results from membrane binding studies and activity assays show that mHwTx-IV has 
similar weak membrane binding interactions to HwTx-IV and a nearly identical inhibitory potency at 
hNaV1.7. In contrast, gHwTx-IV simultaneously displays increased inhibitory activity at hNaV1.7 and 
increased interactions with lipid membranes.  
Peptide–lipid membrane interactions were studied in fluid and raft-like model membranes of both 
anionic and zwitterionic overall charges. In comparison to HwTx-IV and mHwTx-IV, which showed similar 
weak interactions with the model membranes, gHwTx-IV consistently showed the highest affinity to all 
model membranes tested (Figure 3A, B). Furthermore, acrylamide quenching of the fluorescence emission 
of Trp residues on the peptides suggested that gHwTx-IV adopts a superficial position on the membrane 
(Figure 3D). This position on the membrane surface is likely to be facilitated by a combination of 
electrostatic, hydrogen bonding and hydrophobic interactions between the peptide and the phospholipid 
headgroups of the lipid membrane. Several prior GMT–membrane binding studies have proposed that the 
hydrophobic patch present on these spider toxins is important for hydrophobic interactions with the 
membrane and that the charged ring of these spider derived peptides participates in electrostatic interactions 
with the phospholipid headgroups [18, 53-55]. The importance of electrostatic interactions between gHwTx-
IV and the lipid membrane is supported by the observation that gHwTx-IV has a higher affinity for anionic 
lipid membranes (Figure 3 A, B). Furthermore, a global profile of the electrostatic surface potential on the 
surface of gHwTx-IV containing the four mutations (E1G, E4G, F6W and Y33W) is more positive than the 
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same surface on HwTx-IV (Figure 5B), and gHwTx-IV has a higher net charge and residual dipole moment 
than HwTx-IV (Table 3). Together these features can promote GMT electrostatic interactions with the 
phospholipid headgroups of the membrane. The interactions between gHwTx-IV and the lipid membrane are 
likely also facilitated by hydrogen bonding between the indole groups on the side chains of W6 and W33, 
and the phospholipid headgroups of the membrane. Additionally, hydrophobic interactions could also play a 
role in the gHwTx-IV–lipid membrane interaction as is evidenced from the findings that gHwTx-IV has a 
larger hydrophobic patch (Figure 5A) and apolar SASA (Table 3) than HwTx-IV.  
In addition to increased membrane interactions, gHwTx-IV showed a 4-fold increase in inhibition of 
hNaV1.7 compared to both HwTx-IV and mHwTx-IV, which had similar inhibitory potencies. In a previous 
structure-activity relationship (SAR) study with an alanine scan of HwTx-IV, a region at the surface of the 
molecule was proposed to be responsible for the interaction with hNaV1.7 [12]. Specifically, it was 
suggested that the amino acid residues R26, K27 and K32 on HwTx-IV interact with D816, E818 and E811 
on the extracellular loop of voltage sensor domain II of hNaV1.7 (Figure 6) [12]. Our studies with gHwTx-
IV suggest that the combination of the mutations E1G, E4G, F6W and Y33W result in both increased 
membrane binding and increased inhibition of hNaV1.7. These four mutations are part of a hydrophobic 
patch located at the surface of the molecule distinct from the surface formed by the channel binding residues 
R26, K27 and K32 (Figure 6A).  
We propose that the increased potency observed with gHwTx-IV, compared to HwTX-IV, is 
facilitated by membrane-binding interactions. Briefly, electrostatic interactions between gHwTx-IV and the 
membrane would attract the peptide to the membrane surface and additional hydrogen bonding and 
hydrophobic interactions would orient the peptide such that the face containing R26, K27 and K32 is 
available for interactions with hNaV1.7 (Figure 6). In addition, the overall decrease in anionic charge and 
increase in hydrophobicity of gHwTx-IV might further augment interactions between the peptide and 
hNaV1.7 This hypothesis was previously proposed by Revell and colleagues [13], when the authors observed 
an increase in the inhibitory potency of the analogue [E1G,E4G,Y33W]HwTx-IV [21]. In silico docking 
studies suggested that the residues F6 and Y33 form hydrophobic interactions with M750 on hNaV1.7; thus, 
a supporting explanation for the increased activity observed with gHwTx-IV is that the mutations F6W and 
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Y33W would improve the hydrophobic interaction with M750 due to the increased hydrophobic character of 
tryptophan compared to that of phenylalanine and tyrosine [12, 56]. Although we cannot exclude the 
possibility that an increased inhibitory potency on hNaV1.7 and increased membrane binding are 
independent, we propose a model where gHwTx-IV acts by binding both to the membrane and to the target 
channel (Figure 6B). A similar mechanism has been suggested for ProTx-I and ProTx-II, two GMTs that 
also seem to possess distinct surface regions responsible for membrane interaction and for channel 
interaction [18, 48]. Furthermore, the fact the amino acid residues that seem to be involved in membrane 
binding are distinct from those involved in channel binding lead us to postulate that gHwTx-IV will show a 
similar selectivity profile to HwTx-IV, particularly against NaV1.5 which is involved in cardiac muscle 
conduction [16]. This hypothesis is further supported by [E1G,E4G,Y33W]HwTx-IV, an analogue similar to 
gHwTx-IV, which was found to be inactive at NaV1.5 [21]. 
We conclude that by engineering HwTx-IV to increase membrane interactions, we have 
simultaneously designed a peptide with higher activity at hNaV1.7. Overall charge and hydrophobicity play 
important roles both in interactions of gHwTx-IV with hNaV1.7 and with lipid membranes. Two 
predominant theories for GMT–membrane interactions are that the lipid bilayer acts to concentrate the 
peptide at the active site for the purpose of increasing peptide availability at the channel active site and 
secondly that GMT–membrane interactions facilitate access to the voltage sensor domain, which rests at a 
superficial position in the bilayer [57, 58]. The way forward is therefore to study GMTs, model membranes 
and channels in concert to better understanding of the mechanism of action of this tri-molecular complex, 
with the aim of developing peptides with higher inhibitory potency at hNaV1.7. 
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Table 1. Energies and structural statistics for the family of 20 
gHwTx-IV (PDB ID: 5TLR) structures
a
. 
Energies (kcal/mol)  
Overall -990.61 ± 59.80
 
Bonds 25.80 ± 1.58 
Angles 52.39 ± 4.77 
Improper 17.46 ± 2.71 
Dihedral 166.04 ± 2.33 
Van der Waals -150.46 ± 4.73 
Electrostatic -1102.63 ± 61.84 
NOE 0.38 ± 0.03 
Constrained dihedral (cDih) 0.39 ± 0.37 
Mol Probity statistics  
Clash score (>0.4 Å / 1000 atoms) 14.05 ± 3.44 
Poor rotamers 0.78 ± 1.39 
Ramachandran outliers (%) 0.76 ± 1.34 
Ramachandran favoured (%) 85.17 ± 2.84  
MolProbity score 2.38 ± 0.28  
MolProbity percentile 53.90 ± 15.03
c
 
Atomic RMSD (Å)  
Mean global backbone (2–31)d 0.59 ± 0.13 
Mean global heavy (2–31) 1.34  ± 0.17 
Mean global backbone (1–35) 0.99 ± 0.34 
Mean global heavy (1–35) 1.72 ± 0.38 
Distance restraints  
Intraresidue (i – j = 0) 130 
Sequential (|i –j| = 1) 134 
Medium range (|i –j| < 5) 36 
Long range (|i –j| > 5) 90 
Hydrogen bonds
e
 10 
Total 395 
Dihedral angle restraints  
 18 
 19 
1 5 
Total 42 
Violations from experimental restraints  
Total NOE violations exceeding 0.2 Å 1 
Total dihedral violations exceeding 2.0° 2 
a
 Based on structures with highest overall MolProbity score [28]. 
b 
± St Dev 
c
100
th
 percentile is the best among structures of comparable 
resolution; 0
th
 percentile is the worst. 
d
 RMSD calculated in MOLMOL [59]. 
e
 Two restraints were used per hydrogen bond. 
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Table 2. Binding affinity and dissociation rates of HwTx-IV and its analogues to model membranes as 
determined from SPR studies 
POPC POPC/POPS  
(4:1) 
POPC/SM/CHOL 
(2.7:4:3.3) 
POPC/C1P/CHOL 
(2.7:4:3.3) 
Peptide P/Lmax
 a
 
(mol/mol)  
Koff
 b
 
(s
-1
) 
P/Lmax
 
(mol/mol) 
Koff  
(s
-1
) 
P/Lmax 
(mol/mol) 
Koff 
(s
-1
)
 
 
P/Lmax
 
(mol/mol) 
Koff
b 
(s
-1
)
 
 
HwTx-IV 0.01±0.01 N/A negligible N/A 0.03±0.05 N/A 0.05±0.01 N/A 
mHwTx-IV 0.01±0.01 N/A negligible N/A 0.02±0.01 N/A 0.05±0.01 N/A 
gHwTx-IV 0.07±0.02 95±11 0.16±0.03 75±5 0.05±0.01 89±3 0.11±0.01 76±4 
a 
Peptide–lipid ratio (P/L mol/mol) calculated at the end of the association phase (t = 170 s) was plotted as a 
function of peptide concentration (0 – 64 M) and fitted with Prism 7 using one-site specific binding 
analysis; fitted P/Lmax and ± SE are shown;  n = 3. 
b 
Koff was calculated on Prism 7 by fitting the data to an association then dissociation curve based on the 
1:1 Langmuir binding equation at a fixed peptide concentration of 32 M and assuming t0 = 170 s (the point 
during the experiment when peptide injection was ceased); data is ± SE of the fitted parameters n = 3, Koff  
was not calculated for HwTx-IV or mHwTx-IV because the peptides showed minimal binding to the lipid 
bilayers studied. 
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Table 3. Net charge, surface accessible surface area (SASA) and residual dipole moments of HwTx-IV and 
gHwTx-IV 
Peptide Net charge
a
 Total SASA
b
 
(Å
2
) 
Polar SASA
b
 
(% of total 
SASA) 
Apolar SASA
b
 
(% of total 
SASA) 
Residual dipole 
moment
a
 
(Debye) 
HwTx-IV +4 3088.98 42.3% 57.7% 70.58 
gHwTx-IV +6 3019.41 37.9% 62.1% 80.76 
a 
Net charge and residual dipole moment calculated using the g_dipoles tool on GROMACS 
b 
SASA calculated using GETAREA: http://curie.utmb.edu/getarea.html. 
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Figure 1. HwTx-IV (PDB ID:2M4X) shown as a representative GMT. The peptide is colored by residue 
type with hydrophobic (green); positively charged (blue); negatively charged (red) and polar uncharged 
(white). (A) Ribbon representation of HwTx-IV with the inhibitory cystine knot (ICK) motif formed by 
three disulfide bridges (yellow) consisting of cysteine amino acid residues with the C1-C4, C2-C5, C3-C6 
connectivity. (B) Surface representation showing the conserved hydrophobic patch and charged ring 
typically found in GMTs extracted from spider venom. (C) Sequence alignment of HwTx-IV, mHwTx-IV 
and gHwTx-IV. The sequences are aligned along the cysteine residues (bold black), amino acid 
modifications on mHwTx-IV and gHwTx-IV are underlined and * represents C-terminal amidation. 
Figure 2. NMR analysis of HwTx-IV and its analogues. (A) Secondary H shift comparisons of synthetic 
HwTx-IV, mHwTx-IV and gHwTx-IV. The peptides showed good backbone alignment except at or near 
positions where mutations were present. Residue numbers of HwTx-IV and its analogues are shown on the 
x-axis. (B, C) NMR solution structure of gHwTx-IV (PDB ID: 5TLR). (B) The 20 best conformers as 
determined by lowest energy of minimization and highest MolProbity scores are superimposed with 
disulfide bridges shown in yellow. (C) Mutated residues (G1, G4, W33 and W6) of gHwTx-IV are shown in 
white.  
Figure 3. Interactions of HwTx-IV and its analogues with model membranes. (A) Surface plasmon 
resonance sensorgrams obtained at peptide concentrations of 32 M. Peptides were injected for 180 s onto 
lipid bilayers deposited onto the surface of a L1 chip. (B) Concentration–response curves obtained by 
plotting the amount of peptide bound to lipid (P/L mol/mol) at the end of peptide injection (t = 170 s) as a 
function of the peptide concentration (M) injected over the lipid bilayer. All data points represent the mean 
(± SE) of three replicates. (C) Trp fluorescence emission spectra of 12.5 M gHwTx-IV or HwTx-IV upon 
titration with a suspension of POPC/POPS (4:1) LUVs (0–4 mM). The fluorescence emission spectrum of 
HwTx-IV does not display a shift upon titration with lipid vesicles, whereas the fluorescence emission of 
gHwTx-IV showed a blue shift of 7 nm. (D) Quenching the Trp fluorescence emission intensity (excitation 
at 290 nm and emission at 350 nm) of 12.5 M HwTx-IV, gHwTx-IV and L-Trp in the presence of 1 mM 
POPC/POPS (4:1) LUVs upon titration with acrylamide. The acrylamide quenching efficiency was 
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compared by fitting the data to the Stern-Volmer equation (I/I0 = 1) and calculating the Stern-Volmer 
constant (KSV) [40]. Acrylamide efficiently quenched the fluorescence emission of L-Trp (KSV = 49.1 ± 2.5 
M
-1
) and HwTx-IV (KSV = 48.4 ± 1.2 M
-1
) in lipid vesicles. Fluorescence emission of gHwTx-IV was less 
efficiently quenched by acrylamide when in the presence of LUVs (KSV = 37.5 ± 1.5 M
-1
) compared to 
buffer (KSV = 44.2 ± 2.0 M
-1
); however, the small difference between gHwTx-IV KSV values in lipid and 
buffer indicated a shallow positioning of the peptide in the membrane.  
Figure 4. Inhibitory activity of HwTx-IV and its analogues at hNaV1.7 in SH-SY5Y cells. Inhibition 
was monitored by following the fluorescence emission of the FLIPR calcium 4 dye. (A) Activation kinetics 
of HwTx-IV and the two analogues after activation by veratridine is shown at concentrations near the 
respective IC50 values of each peptide and at 1 M. Activation was a measure of calcium influx into the 
cells. HwTx-IV, mHwTx-IV and gHwTx-IV inhibited the activation kinetics of hNaV1.7 as is evidenced in 
their slower slopes of activation (HwTx-IV = 0.0196 ± 0.0006 fluorescence intensity/second; mHwTx-IV = 
0.0143 ± 0.0003 fluorescence intensity/second; gHwTx-IV = 0.0257 ± 0.0009 fluorescence intensity/second) 
compared to veratridine (activation slope = 0.0609 ± 0.0026 fluorescence intensity/second). (B) Dose-
response curves of HwTx-IV and of the two analogues are shown. Fluorescence emission data were 
normalized to the maximum and minimum signals for each peptide and data were fitted as Fmax against 
concentration using a one-site specific binding curve with Hill slope. Data points are the mean ± SE (n = 4). 
Fitting of the dose–responses shows that gHwTx-IV is the most potent inhibitor (IC50 = 7.55 ± 1.54 nM), 
whereas HwTx-IV (IC50 = 32.4 ± 4.74 nM) and mHwTx-IV (IC50 = 30.8 ± 5.18 nM) have similar inhibitory 
potencies. An apparent inhibition of hNaV1.7 at low concentrations is evident on the curve and is a false 
positive effect often seen at low peptide concentrations. 
Figure 5. Surface profiles and electrostatic surface potential profiles of HwTx-IV and gHwTx-IV. (A) 
Surface profiles of HwTx-IV (PDB ID: 2M4X) and gHwTx-IV (PDB ID: 5TLR) highlighting the 
positioning of E1, E4, F6 and Y33 on HwTx-IV and the corresponding mutations (G1, G4, W6 and W33) on 
gHwTx-IV. Peptides are colored by residue type including hydrophobic (green), positively charged (blue), 
negatively charged (red) and polar uncharged (white), showing a notable increase in the hydrophobic area of 
gHwTx-IV compared to HwTx-IV. (B) Electron density profiles of HwTx-IV and gHwTx-IV oriented to 
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show the face possessing the mutations on gHwTx-IV or corresponding native amino acids on HwTx-IV. 
gHwTx-IV has a more positive surface on the face possessing the four mutations compared to the equivalent 
face on HwTx-IV. Electron density distribution bars show a range from -5.0 (red) to +5.0 (blue).  
Figure 6. Lipid interaction surface and channel binding region of gHwTx-IV. (A) Surface profiles of 
gHwTx-IV oriented to show that the hydrophobic patch possessing the four mutations (E1G, E4G, F6W and 
Y33W (green)) on gHwTx-IV is on a distinct face from the surface possessing the residues forming the 
channel binding region (K27, R26, and K32 (purple)) [12]. (B) An illustration of the voltage sensor domain 
II and pore of hNaV1.7 channel is shown highlighting gHwTx-IV, the voltage sensor domain II, and the key 
residues identified as important for the activity of HwTx-IV (E811, D816 and E818 ) are underlined [12]. 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 30 
 
Figure 1 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 31 
 
Figure 2 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 32 
 
Figure 3 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 33 
 
Figure 4 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 34 
 
Figure 5 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 35 
 
Figure 6 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 36 
 
Graphical abstract 
